Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
8
×
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
8
×
fda
8
×
indiana blog main
indiana top stories
life sciences
8
×
national blog main
national top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
8
×
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
clinical trials
national
cancer
eli lilly
amgen
drugs
novartis
startups
teva pharmaceutical
abbvie
allergan
astrazeneca
avexis
What
fda
8
×
drug
bio
roundup
won
approval
drugs
new
approved
class
companies
developed
medicines
migraine
news
oral
activity
agency
ahead
aimmune
allergy
amgen
approvals
arguments
asco
august
awarded
big
biogen
biotech
branded
busy
cancer
candidates
choices
clamped
commercialized
commissioner
competitors
consumers
Language
unset
Current search:
fda
×
biotech
×
" detroit top stories "
×
" san diego top stories "
×
" life sciences "
×
fda
×
@xconomy.com
4 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
4 years ago
Aimmune Awarded First FDA Approval for a Peanut Allergy Therapy
@xconomy.com
5 years ago
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More
@xconomy.com
5 years ago
Bio Roundup: Generic Drugs Graft, ASCO Ahead, ElevateBio Rises & More
@xconomy.com
5 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
6 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines